HPN-100: Phase III started

Hyperion began a 4-week, double-blind, crossover, U.S. Phase III trial to compare oral HPN-100 vs. Buphenyl sodium phenylbutyrate in about 44 patients. Hyperion has an SPA from FDA for the trial. Pati...